Eetu Valkama

Eetu Valkama

Auto-generated profile, based on publicly available information

Eetu Valkama

University of Eastern Finland - Kuopio Campus, Kuopio, Finland

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 April 2026 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
EVEetu Valkama
Eetu Valkama
ETElisa Toropainen
Elisa Toropainen
SSSimar Pal Singh
Simar Pal Singh
AVAnnika Valtari
Annika Valtari
AKAli Koskela
Ali Koskela
JPJooseppi Puranen
Jooseppi Puranen
Retinitis pigmentosa (RP) is an inherited and untreatable retinal dystrophy that leads to blindness at an early age. Cyclic guanosine monophosphate analogue, 8- bromo- β- phenyl- 1, N²- ethenoguanosine- 3', 5'- cyclic monophosphorothioate Rp- isomer (CN03), has shown preclinical promise as systemic treatment in an RP mouse model. We explored intravitreal (IVT) CN03 delivery and resulting biochemical responses in rabbits. To prolong activity, we used poorly water-soluble benethamine (BNE) and benzathine (BNZ) salts to sustain CN03 release. Crystallinity, particle size, and solubility of CN03-BNE (385.4 ± 37.07 µM) and CN03-BNZ (275.9 ± 9.24 µM) in vitreous humor were determined. Suspension of 15% CN03-BNZ showed dissolution half-life of 7.40 ± 0.86 days in vitro and CN03 release of one month after IVT injection in rabbits. Ex vivo in retina lysates, CN03 showed concentration-dependent inhibition of PKG kinases. Furthermore, downregulation of PKG-related kinases and RP-linked cellular pathways (e.g., calmodulin, PI3K-AKT-mTOR, and NF-κB) in rabbit retina and peripheral blood monocytes (PBMC) were seen after IVT injection of CN03-BNZ suspension. Kinase inhibition profiles in the retina and PBMCs overlapped, but plasma CN03 levels were much lower than in the retina. PBMC kinase activity is a potential biomarker for retinal kinase inhibition, warranting further studies in disease state models. Overall, intravitreal delivery of cGMP analogue CN03 as a poorly water-soluble salt demonstrates kinase inhibition and sustained ocular delivery. These results lay the foundation for further translational studies towards intravitreal treatment of the RP with cGMP analogues.

3 August 2026 in International Journal of Pharmaceutics
Verified
Journal Article
Open access
TSTeemu Sorsa
Teemu Sorsa
IPIuliia Pilipenko
Iuliia Pilipenko
EVEetu Valkama
Eetu Valkama
HKHelena Kähärä
Helena Kähärä
MMMarcin Marczak
Marcin Marczak
ASAstrid Subrizi
Astrid Subrizi

2 June 2026 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
EVEetu Valkama
Eetu Valkama
ETElisa Toropainen
Elisa Toropainen
SSSimar Pal Singh
Simar Pal Singh
AVAnnika Valtari
Annika Valtari
AKAli Koskela
Ali Koskela
JPJooseppi Puranen
Jooseppi Puranen

19 November 2026 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Open access
JLJonna Laitinen
Jonna Laitinen
EVEetu Valkama
Eetu Valkama
KVKati-Sisko Vellonen
Kati-Sisko Vellonen
VKVilma Kuusivaara
Vilma Kuusivaara
ETElisa Toropainen
Elisa Toropainen
ASAstrid Subrizi
Astrid Subrizi